haemophilia
-
First of Its Kind Gene Therapy Treatment Approved for Hemophilia
A novel medication for hemophilia B has just been approved by the U.S. Food and Drug Administration. The treatment is a form of gene therapy, intended to replace a dysfunctional gene that leaves people unable to control their bleeding. It’s expected to cost $US3.5 ($5) million per patient.